(Q50502190)

14 March 2018

title

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. (English)

1 reference

14 March 2018

0 references

1 reference

human Coronavirus NL63

0 references

Human coronavirus 229E

0 references

0 references

Volker Thiel

0 references

Marcel Alexander Müller

Marcel A Müller

0 references

Christian Drosten

1 reference

14 March 2018

author name string

Javier Carbajo-Lozoya

series ordinal

1 reference

14 March 2018

Stephan Kallies

series ordinal

1 reference

14 March 2018

Albrecht von Brunn

series ordinal

1 reference

14 March 2018

publication date

10 February 2012

1 reference

14 March 2018

published in

Virus Research

1 reference

14 March 2018

volume

165

1 reference

14 March 2018

issue

1 reference

14 March 2018

page(s)

112-117

1 reference

14 March 2018

In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Immunophilins: for the love of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Dendritic Cell-Specific Antigen Delivery by Coronavirus Vaccine Vectors Induces Long-Lasting Protective Antiviral and Antitumor Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Cyclosporin A inhibits vaccinia virus replication in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Hosting the severe acute respiratory syndrome coronavirus: specific cell factors required for infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Cyclosporin A inhibits the replication of diverse coronaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Severe acute respiratory syndrome: identification of the etiological agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Plaque assay for human coronavirus NL63 using human colon carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

FKBP family proteins: immunophilins with versatile biological functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Specific inhibition of hepatitis C virus replication by cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Coronaviruses post-SARS: update on replication and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

FK506, a secondary metabolite produced by Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection in cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

SARS: systematic review of treatment effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Therapies for coronaviruses. Part I of II -- viral entry inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Identification of a new human coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Identification of host factors involved in coronavirus replication by quantitative proteomics analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Quantitative proteomics analysis reveals BAG3 as a potential target to suppress severe acute respiratory syndrome coronavirus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.02.002

Human coronaviruses: what do they cause?

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22349148

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22349148

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cyclophilin inhibitors for the treatment of HCV infection.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22349148

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2012.02.002

1 reference

14 March 2018

1 reference

14 March 2018